FindTrial
Sign In

BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514783-78-00
Acronym
20U-0014
Enrollment
82
Registered
2024-10-29
Start date
2024-10-29
Completion date
Unknown
Last updated
2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychological disorders: PTSD; Anxiety disorders

Brief summary

Beck’s anxiety index between the first and second week.

Detailed description

Effect of CBD on Fear extinction (i.e. physiological responses and subjective fear), Effect of CBD on stress regulation with the Maastricht Acute Stress Test (MAST; i.e. Subjective stress, physiological responses, alpha-amylase and cortisol), Effect of CBD on Sleep quality (i.e. questionnaires and a sleep watch)

Interventions

DRUGSoftisan 378
DRUGCannabidiol

Sponsors

Universitair Medisch Centrum Utrecht
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Beck’s anxiety index between the first and second week.—

Secondary

MeasureTime frame
Effect of CBD on Fear extinction (i.e. physiological responses and subjective fear), Effect of CBD on stress regulation with the Maastricht Acute Stress Test (MAST; i.e. Subjective stress, physiological responses, alpha-amylase and cortisol), Effect of CBD on Sleep quality (i.e. questionnaires and a sleep watch)—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026